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Induced Differentiation of Erythroleukemia
Cells by Hexamethylene Bisacetamide: A
Model for Cytodifferentiation of Transformed
Cells
by Paul A. Marks* and Richard A. Rifkind*
There is considerable evidence that malignant transformation need not eliminate the potential for a cell
to express its developmental capabilities. This review explores the process whereby polar compounds, hex-
amethylene bisacetamide (HMBA) in particular, induce murine erythroid leukemoid cells (MELC) toexpress
the differentiated erythroid phenotype, including hemoglobin production and cessation ofcell division. This
is a multi-step process which, although the mechanisms ofaction ofHMBA are not yet fully understood, is
amenable to experimental definition and analysis. Early effects, including changes in protein kinase C ac-
tivity, in ion transport, and in expression of certain nuclear proto-oncogenes, have been examined in rela-
tion to the onset ofterminal cell differentiation. This experimental experience has formed the context for
initiatingpreliminary clinical studiesdesignedtoexaminethephannacologyofHMBAandtoexplore itspoten-
tial for modifying the natural history ofcancer.
Introduction
Characterization ofinducer-mediated alterations in the
phenotype oftransformedcells, employinghexamethylene
bisacetamide (HMBA-induced murine erythroleukemia
(MEL) cell differentiation as a model, has provided con-
siderable understanding of the changes involved in this
complex, multistep process (1-3). These investigations
have provided, in part, a basis for considering the use of
cytodifferentiation agents to overcome the maturation de-
fect commonly associated with celltransformation, and to
induce loss of proliferative capacity, as an approach to
therapy of various tumors (4-8).
Studies ofHMBA-induced MEL cells havegenerated a
considerable body of knowledge about the process by
which a proliferating population of precursor cells, with
the potential for expressing a differentiated phenotype (in
this case anerythroid cellphenotype)withdraws from the
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cell division cycle and expresses those genes characteris-
tic ofthe differentiated phenotype. However, our under-
standingoftheprocessisfarfromcomplete. We are only
beginning to define the mechanisms by which these cells
receive proliferative or differentiation signalsfrom their
environment and the ways in which these signals are
transduced to alternuclearevents, such as DNA replica-
tion and specific gene expression.
This review focuses on HMBA-induced MEL cell
differentiation to the terminal erythroid phenotype. It
will summarize studies ofinduceraction duringthe early,
latentperiod andthelater, irreversible alterations involv-
ingexpressionofgenesforproducts characteristics ofthe
differentiated erythroid phenotype. We will also review
studies with celllines in culture that haveprovided aba-
sis for phase I clinical trials with HMBA as a potential
cancer therapy.
Potential of Transformed Cells to
Differentiate
The polarcompound, HMBA, can circumvent the virus-
induced block ofMEL cell development and cause these
cells to differentiate with loss of proliferative capacity
(8,9). Thus, transformation does not eliminate the poten-MARKS AND RIFKIND
tial of MEL cells to express their genetic program of
erythroid differentiation (1-3). Additional evidence that
tumor cells are notnecessarily irreversibly blocked with
respect to differentiation derives from studies ofa num-
ber of systems. For example, compounds structurally
related to HMBA, aswell asanumberofotheragents, can
induce the expression ofdifferentiated characteristics in
MEL cells, as well as a variety ofdifferent transformed
cells invitro (Table 1)(1-3,8-32). This concept is also sup-
ported by the behavior of temperature-sensitive trans-
formingvirusesthatblocknornal development atpermis-
sive temperatures but permit expression of the
differentiatedphenotype atnonpermissive temperatures
(33,34). Other studies that support this hypothesis con-
cern malignant teratocarcinoma cells that, implanted into
the inductive environment of the early mouse embryo,
differentiate and contribute to the normal organs ofthe
chimeric mouse (35).
HMBA-lnduced MEL Cell Commitment
to Terminal Differentiation
MEL cells are virus-transformed erythroid precursors,
apparently blocked in development at a stage compara-
ble to that oftheerythroid-colony formingcell, the CFUe
(2,3). They can be passaged in culture indefinitely while
retaining their potential for expression of the differen-
tiated erythroid phenotype (8). Friend and colleagues (8)
first demonstrated that MEL cells in culture with
dimethyl sulfoxide are induced to express that differen-
tiatedphenotype. Subsequently, we investigated the rela-
tionship between the structure and activity ofinducing
compounds (36). It was found that the polar group was
critical to inducer activity. Further studies identified a
newgroup ofpotentinducers, thepolymethylene bisaceta-
mides, ofwhich HMBAis amongthe mostpotent(Fig. 1)
Table 1. Transformed cells that can be induced to differentiate by
HMBA to other polar compounds (1-26).
Cell type Cell source
Cell lines
Mouse
Rat
Canine
Human
Primary cell cultures
Human
Erythroleukemia
Teratocarcinoma
Hepatic tumor
Neuroblastoma
Mammary tumor
LB myeloblast
Kidney epithelial carcinoma
HL-60 promyelocytic leukemia
Melanoma
Colon carcinoma
Bladder carcinoma
Glioblastoma multiforma
T cell
B cell
Colon carcinoma
Bladder carcinoma
Acute myeloid leukemia
Melanoma
0 0
11 11
CH3- C- NH - (CH2)6 - NH - C- CH3
FIGURE 1. Hexamethylene bisacetamide (HMBA).
(9,37,38). Other agents have also been shown to be effec-
tive, to a greater or lesser extent, as differentiation in-
ducers (1-3).
Culture ofMEL cells with HMBAinitiates expression
ofa developmental program similarto that observed dur-
ing normal terminal erythroid differentiation. HMBA-
induced differentiationofMEL cellsisnot, however, iden-
tical to that ofnormal erythropoiesis (1-3). For example,
erythropoietin, the hormone involved inmaintainingthe
viability andproliferation ofnormal erythroidprecursor
cells, is neither requiredfor, nor stimulates, proliferation
ofMEL cells. HMBA-induced differentiation ofMEL cells
leads to relatively few cells that actually reach the non-
nucleated, mature erythroid stage of development.
Inducer-mediated differentiation ofMEL cells is not as-
sociated with elimination of the viruses.
The kinetics ofinducer-mediated commitment ofMEL
cells to terminal cell division is consistent with a stochas-
tic or probabalistic process (39,40). Upon addition of
HMBA to MEL cells, such as line 745-DS19 (a clone de-
rived in ourlaboratory from the cell line originally devel-
oped by Charlotte Friend), there is alatentperiod ofap-
proximately 10 to 12 hr during which there is no
detectable commitment to terminal differentiation. Com-
mitment is defined as the capacity of cells to express
characteristics ofthe erythroid-differentiated phenotype,
including loss of proliferative capacity, upon removing
them from HMBA (39,40). This early or latent period is
followed by a period during which an increasing propor-
tion ofthe population express characteristics ofterminal
differentiation (Fig. 2).
HMBA-mediated MEL cellterminal differentiation is a
multistep process (41,42). Duringthe earlyperiod, the in-
ducer initiates a number ofmetabolic changes that pre-
cede irreversible commitment. Amongthese changes are
alterations in membrane permeability that involve so-
dium, potassium, and calcium flux(43-45), alterations in
membrane fluidity(46,47), changes in cell volume, atran-
sient increase in cyclic AMP concentration (48-49), a
prompt increase in membrane associated protein kinase
C (PKC) activity, the appearance inthe cytosol ofa Ca2+
andphospholipid-independent form ofPKC, presumably
generated by proteolytic cleavage of membrane-bound
PKC (50), and a change in expression of a number of
genes, includingc-myb, c-myc, c-fos, andp53gene(51-54).
Duringthisearlyperiod, asindicated above, commitment
(as assayed by the capacity of cells to express terminal
differentiation despite removal ofthe inducer) is not de-
tected (Fig. 3).
Upon becoming committed, morphological and chemi-
cal changes occurinMEL cells that are similartonormal
erythroid terminal cell differentiation. These include the
coordinated expression of a number of genes, including
genes for the al andpmaj globin, the heme synthetic en-
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FIGURE 2. HMBA-induced MEL cell commitment to terminal cell divi-
sion and hemoglobin accumulation. Commitment was assayed by
transfer ofcells from suspension culture with HMBAto Petri dishes
(2.5cm indiameter) containinga semi-solid medium(1.8% methylcel-
lulose)without inducer. Cells wereplated to assure that eachwas sin-
gle. Theplates wereincubated for5days at370C andscoredforcolony
size and benzidine reactivity. A cell was scored as committed if it
yielded a colony of c 64 cells that was benzidine reactive.
zymes anderythroid specific membraneproteins, aswell
as suppression of DNA replication and suppression of
rRNA synthesis (1-3). From studies with variant MEL
cells, blocked at different steps in the inducer-mediated
developmental pathway, evidence has accumulated that
the coordinated expression of these inducer-mediated
changes ingene expression does not necessarily involve
an obligatory sequential series ofsteps(55,56). Forexam-
ple, with variant cell line 745A-DR10, HMBAinduces ac-
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cumulation of aI and Pmaj globin without initiating com-
mitment to terminal cell division (55). Likewise, hemin
induces MEL cellsto accumulate globinmRNAbutfails
to induce commitment to terminal cell division (56-58).
Modulation of Gene Expression
During the early period, HMBA induces a modulation
in expression of a number of genes, among which are
c-myb, c-myc, c-fos, andp53 (51-54). These genes control
products that are localized in the nucleus andmaybe in-
volved in the regulation ofgene expression and cell repli-
cation (59-63). However, the specific action oftheprotein
products ofthesegenes is notknown. In MEL cellsin cul-
ture with HMBA, the level of c-myc mRNA decreases
markedly within the first hour ofculture. A decrease in
c-myb mRNAlevel occurs within 1 to 4 hr, whereas c-fos
mRNA, whichis almostundetectable inuninduced MEL
cells, begins to accumulate within about 4 hr ofonset of
culture, reaching a maximum by about 18 to 24 hr. p53
mRNAlevels do not change appreciablyin MEL cells in
culture withHMBAfor atleast 48hr. With continued ex-
posure to HMBA, furthermodulation ofthe c-myb, c-myc,
and c-fos genes occur. The level of c-myc mRNA rises
back toward that ofuninduced cells by about 12 hr and
remains there for at least the ensuing 36 hr, while the
elevated level of c-fos mRNA remains essentially un-
changed.
By comparison, by 12 hr, the level ofc-myb mRNA has
increased almost to control levels, from its early nadir,
then falls again to an undetectable level by 24 to 36 hr,
where itremains for the duration ofculture with inducer.
That inducer-mediated suppression ofc-myb mRNAmay
be an important factorin the recruitment ofcells to com-
mitment is suggestedby several lines ofevidence: a) con-
tinued suppression ofc-myb mRNAlevel(but not that of
DNA Synthesis- Terminal Divisions
Prolonged G6
DNA Breaks
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FIGURE 3. Schematic representation ofmodel ofHMBA effects in inducing MEL cells to terminal differentiations (for details see text). Modulation
in metabolic function and gene expression is indicated as follows: (I) decreased; (T) increased. The early, latent period is indicated as "uncommit-
ted" andisapproximately 12 hrin durationforMEL cellline, 754A-DS19, in culture with 5mM HMBA. Recruitment ofMEL cellsto the commit-
ted state is detectable by 12 to 14 hr, and the proportion ofcells committed increases, in a stochastic manner, to levels of >95% by 48 to 60 hr
in culture with HMBA. The horizontal list ofvarious characteristics gives an indication ofthe sequence ofevents in relation to onset ofculture
with HMBA, but time in culture is not represented in a linear scale.
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c-myc) is characteristic of progressive recruitment of
MEL cells to terminal cell division; b) hemin, which
initiates globin mRNA accumulation, but not commit-
ment, does not suppressc-myb mRNA; c) dexamethasone
inhibits HMBA-induced commitment andinhibits the late
(> 12 hr) suppression of c-myb mRNA, but does not
modify the changes in c-myc or c-fos mRNA or p53 pro-
tein that occur in response to HMBA alone.
Recent studies inourlaboratories (64) have shown that
the level of the c-myb and c-myc proteins parallel the
changes in c-myb and c-myc mRNA, respectively, with
the exception that the c-myb proteinremains elevated at
24 hrwhenthe c-myb mRNAbegins tofall to almost un-
detectable levels and then the protein level fallsmarkedly.
The level ofp53 protein decreases to very lowvalues be-
tween 4 and8 hrin, culture with HMBAandthenremains
low, even though, as noted already, p53 mRNA levels do
not decrease appreciably during this time. These studies
suggest that HMBA-mediated modulation of the c-myc
and c-myb proteins is exerted primarily by regulation of
c-myc and c-myb mRNA accumulation, whereas the level
ofp53protein is modulatedby mechanisms actingat the
level oftranslation or posttranslation.
The early modulation ofexpression ofc-myb, c-myc, and
c-fos gene expression appears tobeundercontrol mecha-
nisms different from those involved in the regulation of
the alterations inexpressionofthesegenes occurringdur-
ing the period ofrecruitment of cells to commitment to
terminal differentiation(53). This is suggestedbythefind-
ingthatagents thatinhibit HMBA-induced MEL expres-
sion ofthe differentiated phenotype, such as the steroid
dexamethasone, or the tumor promoter, 12-O-tetra-
decanoylphorbol-13-acetate (TPA), do not alter the
HMBA-induced changes in gene expression during the
early period, but will block HMBA-induced suppression
of c-myb during the later period (53,64).
Evidence that the c-mycproduct has arole in differen-
tiation has been supportedby studies showingthatMEL
cells stably transfected with plasmid containing c-myc
codingsequences, which are constitutively expressed, fail
to differentiate in response to dimethyl suifoxide (65).
Such results, taken together with studies cited earlier,
suggest that there may be a particular time during the
course ofHMBA-induced MEL cell differentiation when
changes inexpression ofthe myc,myb,fos, andp53genes
are critical to themultistep process thatleads to expres-
sion of the terminal differentiated phenotype.
Modulation of Expression of Globin
Genes
In ourlaboratory, several features ofDNA and chroma-
tin structure in theglobin gene domains have been exam-
ined in relation to inducer-mediatedmodulation ofexpres-
sion ofthe a- andp-globingenes(66-70). We havereported
that certain structuralpatterns ofchromatin and DNA,
commonly associatedwith activelytranscribedgenes, are,
in fact, detected in the al- andPmaj-globin gene domains
ofuninducedMEL cells despite therelative inactive tran-
scription ofthesegenes. These include apattern ofDNA
hypomethylation ofbothgenes, anincrease of2- to 3-fold
in the sensitivity of the globin gene DNA domains to
DNase I digestioncomparedwithgenesthatare nottran-
scribed in erythroid cells (71). There is disruption ofthe
normal nucleosome pattern acrossthe al- andPmaj-globin
gene domain. Whereas HMBA causes no evident change
in the pattern ofmethylation ofDNA in theglobin gene
domains (71), the inducer does cause certain changes in
chromatin structure, including appearance of DNAse I
hypersensitive sites within 100 base pairs 5' ofboth the
al- and Pmaj-genes (66,67,71) and the appearance of
another DNAse I hypersensitive site about 3000 base
pairs upstream of the cap site of the Pmaj-globin (72).
HMBA initiates additional nucleosome disruption, limited
to the transcribed regions ofthea,- andPmaj-globin gene
domains (73). Time-course studies on the appearance of
alterations in chromatin in MEL cells inducedby HMBA
indicate that these changes, which are detectable within
12 to24hr(thatis,withinapproximately 1 to2cell cycles),
precede the onset of accelerated transcription. Studies
with variantcell lines, such as 745A-R1, which are resis-
tant to HMBA-mediated induction, provide further evi-
dence that changes in chromatin structure precede onset
of accelerated transcription of the globin genes (68). In
these cell lines, HMBA induces certain limited changes
in chromatin structure, but not the complete pattern ob-
served in HMBA-sensitive cell lines such as 745A-DS19.
Taken together, the present data indicate that HMBA
causes selective and dramatic increasesintherate oftran-
scription ofglobingenes that are dependent upon anum-
ber ofspecific changes in chromatin configuration within
the globin gene domains. These changes in globin gene
related chromatin structure andglobingene transcription
are part ofthe late modulation ingene expression asso-
ciated with HMBA action on MEL cells.
Mechanism of Action of HMBA
Aworkingmodelforthe effects ofHMBAon MEL cells
is presented in Figure 2. The mechanism of action of
HMBA is not known. There is evidence that HMBA and
related polar compounds cause a significant decrease in
the levels ofphosphatidylinositol metabolites, including
inositoltriphosphate and diacylglycerol, within2 hrofon-
setofculture(74). Diacylglycerol activates the Ca2+ and
phospholipid dependentPKCactivity(75). The tumorpro-
moter TPA, which activates PKC and for which PKC is
a specific receptor, can suppress HMBA-induced differen-
tiation in MEL cells (76,77). We have recently reported
evidence that PKC activity has arole in inducer-mediated
modulation oflategene expression in MEL cell differen-
tiation, based on the followingfindings (50): a) HMBA in-
ducestheformationofasoluble, proteolytically activated
form ofPKC thatis catalytically active in the absence of
Ca2+ andphospholipid; b)the protease inhibitor, leupep-
tin, blocks formation ofthis activated form ofthe kinase
and inhibits HMBA-induced MEL cell hemoglobin ac-
cumulation; c)TPA, which causes depletion oftotal PKC
activity, inhibits HMBA-induced MEL cell terminal dif-
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ferentiation but does not prevent the inducer-mediated
early modulation in expression ofc-myc, c-myb, and p53
genes; d)MEL cells depleted ofPKC activitybyTPAare
resistant to induction by HMBA; e)removal ofTPAleads
to restoration of MEL cell sensitivity to HMBA, cor-
related withprogressive reaccumulation ofPKC activity.
If, as suggested, PKC activation has a role in the path-
way ofHMBA-induced modulation ofgene expression and
consequent differentiation andloss ofcapacity forcell di-
vision, itmayinvolve thephosphorylation ofproteins crit-
ical to the regulation ofgene expression and DNA repli-
cation.
There is evidence for other inducer-mediated events
that may also be involved in the pathway leading to ex-
pression of the differentiated phenotype in MEL cells.
These include single strand breaks in DNA (78-80),
changes in configuration of chromatin structure (81,82),
and expression or suppression of specific oncogenes (as
described above) (51-65). Recently, it hasbeen shown, us-
ingthe technique ofcell fusion, thatMEL cell differenti-
ation may involve a synergistic effect oftwo distinct in-
tracellular reactions (83), one originating from the
inhibition or cessation of DNA replication by diverse
agents, and the otherinvolving areaction triggered spe-
cifically by inducing agents such as HMBA. The former
reaction appears nottobe specifictoMEL cells, whereas
the latter is specific to MEL cells and inducible by
HMBA. Theinducedactivity istransient andinhibitedby
TPA (84,85). Partial purification of the protein factors
responsible forthese reactions hasbeenreported(86,87).
It is not yet clear how these protein factors interact or
howtheymaytrigger erythroid differentiation ofinducer-
treated MEL cells.
Phase I Clinical Trials and
Pharmacological Studies with HMBA
The evidence that HMBA can overcome the develop-
mentalblockassociatedwithtransformation in anumber
of cell lines has provided the basis for evaluating this
agent in treatment ofhuman neoplastic disease. HMBA
has proved to be the most potent inducer of differentia-
tion of a number of transformed cell lines, as well as
severalprimary human cancer cellsgrowninvitro(Table
1). HMBAhasbeen evaluatedinthe National Cancer In-
stitute Division ofCancerTreatment Tumor Screen Pro-
gram and showed notherapeuticbenefitto animalsbear-
ing several murine leukemic and solid tumors and
possessed little or no cytotoxic activity against human
mammary, colon, and lung xenografts in nude mice (88).
These animal models, however, did not replicate the in
vitro conditions that appear to be critical for induced
differentiation oftransformed celllines, inparticular, the
optimal concentration, which is about 5mMforalmostall
ofthe sensitive celllines, andtherequirementforthe con-
tinuous presence of the inducer over a relatively pro-
longed period for recruitment of transformed cells to
differentiation and loss ofproliferative capacity.
At least three phase I clinical studies of HMBA have
nowbeen performed (at the University ofMaryland Can-
cer Center, at the Johns Hopkins Oncology Center, and
atthe Memorial Sloan-Kettering Cancer Center)(89-93).
These initial phase I studies ofHMBA examined the tox-
icity and pharmacology of the agent administered as a
5-day, continuous infusion schedule repeated every 3
weeks, escalatingfrom a starting dose of4.8g/m2 per day
to 40.0g/m2 per day. Tbxicities consisting ofrenal insuffl-
ciency, hyperchloremic metabolic acidemia/acidosis, and
central nervous systemtoxicity characterizedbyagitation
and delerium limited dose escalation. Whereas these
symptoms were all reversible upon cessation ofthe drug,
thelevel ofadministration, whichwasnotassociatedwith
undesirable side effects (24 g/m2/day), yielded average
concentrations ofthe agent ranging only between about
1 to 1.5mM. More recently, a 10-day continuous infusion,
administered every 4 weeks, was evaluated in a phase I
trial (92, C. Young, unpublished observations). In these
studies, the maximum tolerable dose was approximately
20 g/m2 per day in order to avoid thrombocytopenia,
which was the most prominent dose-limiting toxicity on
the 10-day schedule. At this dose, the mean steady-state
HMBA concentration among different patients ranged
from a low of 0.31 to a high of 3.4 mM.
Ifeffective concentrations ofHMBA or some other ac-
tivepolarcompound canbe achieved clinically, the poten-
tial for inducingproliferating neoplastic cells to express
differentiatedfunctions and decrease their rate ofcell di-
vision has important implications for cancer therapy. It
is also possible that such agents could prove useful in
treatment ofpremalignant lesions. Eventhe ability to de-
crease the body load of cancer cells by the use of a
differentiation-inducing agent couldprove valuable when
used in conjunction with cytotoxic drugs. The in vitro
studies summarized inthis review suggestthat to evalu-
ate HMBA or similar agentsfortheirpotentialtherapeu-
tic effectiveness itwillbe necessary to achieve anoptimal
in vivo concentration ofthe agent; to maintain that con-
centration over aprolongedperiod; and to have markers
that canbe evaluatedfor confirmingthebiological effect
of the agent in modulating the cancer cell phenotype.
Summary
Considerable evidence has accumulatedindicatingthat
transformation does notnecessarilydestroythe differen-
tiation potential of tumor cells. One striking example is
the ability ofpolar compounds, such asHMBA, to induce
leukemic MEL cells to express the differentiated
erythroidphenotype, including cessation ofproliferation.
While the mechanism ofaction ofHMBAhas notyetbeen
fullydefined, itis clearthatinducer-mediated differenti-
ation is amultistep phenomenon. Amongthe early effects
ofthe inducer are a decrease in diacylglycerol concentra-
tion; an increase in membrane-bound PKC activity; the
appearance ofCa2+ andphospholipid independent PKC
activity in the cytosol; alterations in ion transport, and
modulation in expression ofanumber ofgenesincluding
c-myb, c-myc, c-Jbs, andthep53protein. HMBA-mediated
commitment to irreversible terminal differentiation is
first detected at about 12 hr and continues in a stochas-
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tic fashionuntil over95% ofthe population are recruited
to a state ofirreversible commitment to terminal differen-
tiation andterminal cell division by48 to 60hr. Commit-
ment is associated with persistent suppression ofc-myb
gene expression and elevated levels ofc-fosmRNA, while
c-myc mRNA returns to the level in uninduced cells. By
36to48hr, transcription ofthe globingenes hasincreased
by 10- to 30-fold, whereas transcription from the rRNA
genes is suppressed.
The invitro studies with HMBAinduction ofMEL cells
provide a basis for considering polar agents, such as
HMBA, for clinical therapy ofhuman cancers. Based on
these in vitro studies it is likely that, to be effective,
HMBA must be administered in doses that achieve ade-
quate concentrations inthe serum(probably inthe neigh-
borhood of3 to 5mM), thatthese concentrations bemain-
tained over a prolonged period of time, and that the
biological effect ofthe agent be monitored by indices of
theparticular differentiated phenotype ofthe cancerbe-
ing studied.
These studies were supported, in part, by grants from the National
Institutes of Health (CA 31768 and CA-08748).
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